Judgment of the National Green Tribunal in the matter of Shalbjit Singh Vs Punjab State Pollution Control Board & Others dated 21/11/2024. A letter petition dated November 5, 2022 was sent by Shalabhjeet Singh, resident of village Haibatpur, tehsil Derabassi, district SAS Nagar, Mohali complaining that M/s Nectar Life Sciences …
Joe C Mathew / New Delhi July 24, 2008, 0:03 IST Two United States senators have asked the US Food and Drug Administration (USFDA) to provide details of market approvals given to all medicines sold by India's largest drug-maker Ranbaxy in that country. The senators, John Dingell and Bart Stupak, …
Ranbaxy said on Tuesday that UK's English Crown court has quashed the country's Serious Fraud Office (SFO) prosecution of the firm's subsidiary. This has come as a welcome breather for the company, which is facing investigations in US for selling sub-standard drugs. Ranbaxy said that the court also declined an …
BS Reporter / New Delhi July 23, 2008, 0:52 IST Ranbaxy Laboratories today said it has won a two-year-old case against UK Serious Fraud Office (SFO) in the English Crown Court, a morale boosting relief to the domestic drug major. SFO had taken Ranbaxy's UK subsidiary, Ranbaxy (UK), to court …
Two US Congress members have expressed doubts over the quality of inspections conducted by the US Food and Drugs Administration (FDA) on Indian drug manufacturing facilities. Congressmen John Dingell and Bart Stupak have said the ongoing FDA-Ranbaxy row over alleged supply of "fraudulently approved and manufactured" medicines by Ranbaxy in …
P B Jayakumar / Mumbai July 19, 2008, 0:40 IST Amid reports of a US Congress probe against India's largest drug maker Ranbaxy Laboratories, data show that many leading multinational companies such as Pfizer, GlaxoSmithKline, Novartis and Merck are also under the scanner of the US drug regulator, for more …
HIT hard by mounting scrutiny and falling stocks, Ranbaxy CEO and MD Malvinder Singh said a big global pharma company was trying to scuttle the deal with Daiichi Sankyo. "This is part of a larger game of a global innovater company to block low-cost generic drugs,'' he said. According to …
It seems that Ranbaxy's troubles will not end soon. A US congressional committee is launching an investigation into the US Food and Drug Administration's role in handling the allegations that Ranbaxy sold potentially adulterated medicines, said a US media report. The House Energy and Commerce Committee has said that it …
Ranbaxy Laboratories, the leading Indian pharmaceutical firm, has been in the eye of a storm over allegations by US federal investigators about the manufacturing practices followed at its Paonta Sahib plant in Himachal Pradesh. The plant has what is considered the most prestigious certificate in the world for such an …
After rising 15 per cent Wednesday, the Ranbaxy stock resumed its downward journey on reports in the US media that a US Congressional Committee will examine Ranbaxy's drug approvals in the US and potential violations of manufacturing regulations. The committee will also scrutinise the US drug regulator Food and Drug …
AUS Congressional Committee is launching an investigation into whether US Food and Drug Administration (FDA) was lenient in allowing Ranbaxy to sell new drugs in the US market when it was still investigating discrepancies at the Indian pharma major's manufacturing facility in India. The committee will also examine whether the …
The Ranbaxy sale to Daiichi Sankyo could herald a new phase in the evolution of the Indain pharmaceutical industry. In order to cope in a world after the agreement on Trade-related Aspects of Intellectual Property Rights came into force, some of the larger Indian firms pursued the two strategies of …
Ranbaxy Laboratories, Dr Reddy's Laboratories, Nicholas Piramal and other pharmaceutical companies are betting on inlicensing or strategic marketing tie-ups to help grow local sales after India banned copying of patented drugs. According to analysts, Indian drug makers are forging alliances with overseas companies such as CD Pharma, Gnosis SpA, Crawford …
Ranbaxy has signed a collaboration agreement with US-based Merck for drug discovery and clinical development in anti-infective drugs. Ranbaxy and Merck will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates. Ranbaxy will carry out drug discovery and clinical development through Phase IIa clinical trials, with Merck conducting …
After consecutive litigation losses against Pfizer in its bid to grab a market share of the world's largest selling drug, Lipitor, Ranbaxy can now breathe easy. Last week, the Indian company got a shot in the arm, with the US Patent and Trademark Office (USPTO) issuing a a preliminary rejection …
Ranbaxy on Tuesday said that it has entered into a business alliance with Orchid Chemicals & Pharmaceuticals, involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients (raw materials). However, sources said the option of acquiring additional equity in Orchid, and announcing an open offer at …
Ranbaxy Laboratories (Ranbaxy) and Orchid Chemicals & Pharmaceuticals (Orchid) have announced that they have entered into a business alliance agreement involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients (APIs). Additionally, this agreement would establish a framework for enhanced future co-operation between the two companies. …
Ranbaxy Laboratories Ltd has announced the launch of BONISTA- Teriparatide injection for the treatment of Osteoporosis, in collaboration with the Hyderabad-based Virchow Biotech Pvt Ltd. Ranbaxy is the first company to launch this bio-generic product in the world. Commenting on the launch of the product, Mr Sanjeev I. Dani, Senior …
Country's largest drug maker, Ranbaxy, on Thursday announced the launch of 'BONISTA- Teriparatide' injection used in the treatment of Osteoporosis disease in collaboration with Hyderabad-based Virchow Biotech. BONISTA- Teriparatide injection is manufactured by recombinant human parathyroid hormone and Ranbaxy has become first company in the world to launch this bio-generic …
rbx11160, the much-touted first anti-malarial drug developed by drug major Ranbaxy's public-private partnership, will not be out until 2011. The drug may also not be available at a price the poor can afford. A Geneva-based ngo, Medicines for Malaria Venture, has decided to stop funding rbx11160's research. After reviewing the …
ranbaxy in norway: The Norwegian Appeals Court ruled that Ranbaxy Laboratories Ltd's generic version of Lipitor did not infringe Pfizer Inc's patents. Ranbaxy says they will now be able to market their products in Norway. Pfizer markets its cholesterol-lowering drug Atorvastatin as Lipitor. The court ruled that three Pfizer patents …
